Overview - GALT US

Galectin Therapeutics Inc

GALT.US | summary | financial summary | prediction chart | global stock news | news graph | volatility | components |pairs | earnings | dividends | sales | compare

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with nonalcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

symbol	last	change	%chng	name	mcap	sector	wiki
GALT				Galectin Therapeutics Inc	0.260B	Healthcare

	symbol	prev.close	range	chart	target	percent	period	months	due	rating
C	GALT	3.45	0,-0.555,5.392,1.145,-0.555	1.76,1.74,1.74,1.66,1.71,1.84,1.90,2.05,2.00,2.26,2.38,2.91,3.93,3.49,3.31	1.47-2.05	-49.05%	267,114,267	5.1	Jan 4-Sep 27	53.16%

Intraday chart for GALT

Please reload the page if latest figures not showing

Key financials

The following extracted figures are selected by the AI as the most essential for predicting future price movements. The arrows show the how the AI thinks the figure affects the stock price (not the change in the figure)

. operatingIncome	-10M
. . netInterestIncome	-1M
. incomeBeforeTax	-10M
. otherOperatingExpenses	10M
. netIncomeApplicableToCommonShares

. reconciledDepreciation	0M
. netWorkingCapital	12M
. netInvestedCapital	9M
. netDebt	46M
. totalCashFromOperatingActivities	-5M
. freeCashFlow. .	-5M

News for GALT

headline news | recent news | latest news | market news

Chart GALT

Similar stocks g.interference

Galectin Therapeutics Inc	GALT	US	Healthcare	42.5592	260M	-

Myshare aims to provide good clear honest and easy analysis of financial markets using a scientific, teaching and informative approach. We try hard but please read our disclaimer. Pages are provided by ourselves and our users. Register to edit pages and see the documentation

Global news | headline news | recent news | latest news | market news | topics | stock topics

News topics and stories from around the world and in the selected country

US News | headline news | recent news | latest news | market news | recent topics | stock topics

News from major news outlets like BBC, CNN and Reuters

Forecasts | Forecast buy | Forecast sell | Forecast up | Forecast down | Forecast sector

Long term stock predictions using AI reading the financial accounts of each company.

``` ``` ``` ```